MREO Alert: Class Action Deadline Approaches April 6, 2026!

Company Overview and Recent Developments

Mereo BioPharma Group plc (NASDAQ: MREO) is a UK-based, clinical-stage biopharmaceutical company focused on rare diseases (www.globenewswire.com). Its lead candidate was setrusumab (UX143) for osteogenesis imperfecta (OI), a genetic bone disorder. Notably, setrusumab received FDA Breakthrough Therapy Designation in 2024 based on interim Phase 2 data suggesting a rapid and meaningful reduction in fracture rates (www.globenewswire.com). However, in late 2025 Mereo announced disappointing Phase 3 results – neither the ORBIT (pediatric/young adult) nor COSMIC (young pediatric) trials achieved their primary endpoint of reducing annualized fracture rates versus placebo or standard care (www.mereobiopharma.com). Both studies did show statistically significant improvements in bone mineral density (a secondary endpoint) but failed to demonstrate actual fracture reduction (www.mereobiopharma.com). Following this news, Mereo’s ADS price collapsed from $2.31 on December 26, 2025 to $0.29 by December 29, a single-day plunge of ~87.7% (www.prnewswire.com). This implosion erased a large portion of the company’s market value. As of early 2026, Mereo’s market capitalization hovers near $60–65 million, roughly in line with its cash on hand (www.macrotrends.net) (www.panabee.com), reflecting investors’ skepticism about the remaining pipeline.

The sharp stock decline has sparked shareholder litigation. Multiple law firms have announced class-action lawsuits alleging that Mereo misled investors about setrusumab’s prospects (www.prnewswire.com). The complaint claims the company made “overwhelmingly positive” statements about the Phase 3 trials – expressing confidence that setrusumab would significantly reduce fractures – while concealing adverse facts such as internal data indicating the trials were not meeting key endpoints (www.prnewswire.com). When the truth emerged via the December 29 press release (that the trials missed their primary goals), investors suffered heavy losses. Affected shareholders who bought MREO between June 5, 2023 (when upbeat Phase 2 results were first reported) and Dec. 26, 2025 can seek lead-plaintiff status in the class action; the deadline to file is April 6, 2026 (www.prnewswire.com). This legal overhang adds to the challenges facing Mereo as it reassesses its strategy after the trial failure.

Dividend Policy and Shareholder Yield

Mereo BioPharma is an R&D-stage biotech and has never paid any cash dividends on its ordinary shares (www.sec.gov). The company does not anticipate issuing dividends in the foreseeable future, given its lack of earnings and need to conserve cash for drug development (www.sec.gov). This is typical for clinical biotech firms, which tend to reinvest capital into pipeline programs rather than returning cash to shareholders. Consequently, MREO’s dividend yield is 0%, and there is no history of share buybacks or other shareholder yield. Metrics like AFFO or FFO – used in REIT valuation – are not applicable to Mereo, as the company generates no recurring operating cash flow or funds from operations. Instead, investors’ potential return is expected to come from stock price appreciation (contingent on clinical and regulatory success) rather than income. Mereo’s dividend policy reflects its developmental stage and accumulated losses; under UK law the company cannot pay dividends until it has sufficient distributable profits (www.sec.gov), a scenario that remains out of reach in the near term.

Leverage and Debt Obligations

Leverage remains low for Mereo, as the company primarily finances operations through equity and partnership capital. The only significant debt has been a convertible loan note issued to Novartis in 2020 (as part of acquiring a Novartis asset). This £3.8 million note was originally due in February 2023 but was amended and extended to mature on February 10, 2025, with an increased 9% annual interest rate (www.sec.gov). The extension came with additional equity warrants to Novartis as compensation (www.sec.gov). By September 30, 2024, this convertible note (plus accrued interest) was recorded as a ~$5.5 million current liability (due within 12 months) on Mereo’s balance sheet (www.globenewswire.com). No other long-term loans or bank debt are on the books, aside from small lease liabilities for office space (under $1 million) (www.globenewswire.com).

Mereo has since addressed its debt coming due. The Novartis convertible note reached maturity in Q1 2025, at which point it was either repaid or converted to equity (the company has not explicitly detailed the final outcome). Given Mereo’s ample cash reserves relative to this obligation and the stock’s high trading price through 2024, it’s likely the note was settled without strain. As of the end of 2025, Mereo carries no significant interest-bearing debt, leaving it essentially unlevered. This conservative balance sheet means interest expense is minimal (the 9% note interest was only a few hundred thousand dollars per year) and debt maturities are not a pressing risk. Mereo’s capital structure is mostly equity-funded, which limits insolvency risk but puts the onus on equity dilution for future financing.

Cash Runway and Coverage

Mereo’s financial survival depends on its cash reserves and the careful management of expenses. The company has been operating at a net loss, so it relies on funding (equity raises, partner payments, grants, etc.) rather than operating cash flow. As of December 31, 2025, Mereo reported approximately $41 million in cash and equivalents (www.panabee.com). Management projects this cash runway will fund operations into mid-2027, after implementing cost-saving measures in the wake of the setrusumab setback (www.panabee.com). In early 2026, the company announced strategic cuts – delaying or pausing pre-commercial manufacturing activities for setrusumab – to conserve capital while reassessing that program’s path forward (www.panabee.com). These cuts extended the liquidity runway by reducing burn rate. It’s worth noting that Mereo’s cash balance was bolstered in 2024 by at-the-market equity offerings and partnership proceeds, peaking at ~$80.5 million in Q3 2024 (www.mereobiopharma.com). But R&D and trial costs (especially as the Phase 3 studies concluded) consumed tens of millions by year-end 2025.

Coverage ratios in the traditional sense (e.g. interest coverage or dividend coverage) are not meaningful for Mereo right now – the company has no debt service burden beyond trivial interest, and it pays no dividends. Instead, a key coverage metric is how well its cash can cover ongoing operating expenses (primarily R&D and G&A). In 2025, Mereo’s quarterly operating burn was roughly $7–9 million, implying about 4–6 quarters of runway from the start of 2026 given $41 million on hand. Management’s mid-2027 guidance suggests they plan to further scale down spending or secure additional funding to bridge to that point. Indeed, $41 million is relatively low for a biotech with plans for a Phase 3 trial (www.panabee.com). If Mereo proceeds with a large clinical trial (e.g. alvelestat’s Phase 3) without a deep-pocketed partner, its cash would likely be insufficient – meaning additional capital raises could be needed well before 2027. For now, however, the company’s cash position is enough to cover near-term operations and any modest interest or lease payments. Importantly, Mereo has no immediate debt repayments to cover, so its cash is dedicated to funding R&D programs and overhead.

Valuation and Market Performance

MREO’s valuation has been severely impacted by the failure of its lead program. Before the December 2025 readout, investor optimism around setrusumab’s potential had buoyed the stock into the $2+ range (NASDAQ). The subsequent collapse to cents per share wiped out most of the company’s market cap. At a share price around $0.50 in early 2026, Mereo’s market capitalization stands near $60–70 million (www.macrotrends.net). This valuation is only slightly above the company’s net cash holdings (~$41M), implying that the market assigns limited value to Mereo’s remaining drug pipeline. In other words, MREO now trades roughly at “cash value”, with its enterprise value largely reflecting the expected costs and uncertainties of continuing R&D. Analysts note that the primary valuation driver – setrusumab’s commercial prospects – has been materially impaired by the failure to meet the fracture reduction endpoint (www.panabee.com). Without that driver, the stock’s risk/reward is now tied to less certain assets like alvelestat and other partnered programs.

Traditional valuation metrics are difficult to apply given Mereo’s lack of earnings. The company has virtually no recurring revenues (occasional milestone payments have totaled only ~$10M annually (www.macrotrends.net)) and continues to post net losses. Price-to-earnings (P/E) is not meaningful (negative earnings), and even price-to-sales is very high if considering the minimal revenue. Price-to-book (P/B) is a more relevant yardstick in this context: with equity largely comprised of cash, MREO’s P/B is close to 1.0 after the price collapse, indicating the stock trades near book value (mostly cash). By contrast, before the trial readout, MREO traded at a hefty premium to book – reflecting investor expectations of future cash flows from a successful OI drug. Now that those expectations have evaporated, the valuation has reverted to a floor level supported by liquidation value.

For context, many clinical-stage biotechs in similar straits (a lead program failure) see their market values align with cash on hand, unless other late-stage assets exist. In Mereo’s case, some pipeline value might still be warranted for alvelestat and out-licensed compounds, but the market appears to be in “wait and see” mode. Any future re-rating of the stock will depend on concrete progress – e.g. signing a partner for alvelestat’s Phase 3 or salvaging a niche approval for setrusumab based on bone density data. Until then, investor sentiment remains cautious, which is evident in MREO’s depressed share price. It’s also worth noting that at <\$1, the stock risks breaching Nasdaq’s minimum bid requirement (Mereo would need to regain compliance via a price rebound or a reverse split to avoid eventual delisting). Overall, the current valuation reflects deep skepticism, essentially valuing Mereo as a shell of cash plus speculative pipeline optionality.

Key Risks and Red Flags

Mereo faces significant risks and red flags following the events of 2025. Foremost is the failure of the setrusumab Phase 3 trials, which was a major setback for the company’s strategy and credibility. Management had “heavily” prioritized setrusumab’s success – as acknowledged in Mereo’s own filings, the company was highly dependent on the success of setrusumab (along with alvelestat) to drive its future (www.sec.gov). The inability to meet the primary efficacy goal for OI undermines the potential for regulatory approval, which was necessary for any commercial payoff. This raises existential questions for Mereo, since a core part of its pipeline thesis has unraveled. The stock’s collapse and subsequent class-action suit reflect investor concern that prior optimism was unfounded or worse, misleading.

Litigation risk is now on the table. The class-action lawsuits allege that Mereo deceived shareholders by omitting material information about the trials (www.prnewswire.com). For example, while the company projected confidence that setrusumab would reduce fractures, neither Phase 3 study ultimately hit that endpoint (www.prnewswire.com). If evidence shows that internal data or interim analyses indicated trouble (and management failed to disclose that), it could lead to costly legal settlements or penalties. Even if Mereo’s management acted in good faith, the lawsuit will consume resources and could distract leadership at a critical time. The outcome is uncertain, but shareholder suits pose a reputational and financial overhang for the company. At minimum, the situation highlights governance red flags – investors will recall that in late 2022, an activist shareholder (Rubric Capital) criticized Mereo’s governance and pushed through board changes, citing concerns about “misleading statements” and strategic direction. While that conflict was resolved via a cooperation agreement, the recurrence of credibility questions (now via a lawsuit) does not inspire confidence.

Another risk is regulatory compliance and listing status. MREO shares are currently trading well below $1, which is the Nasdaq’s minimum bid price for continued listing. If the stock remains under $1 for an extended period (typically 30 consecutive trading days), Mereo will receive a deficiency notice and then have 180 days (plus potential extensions) to cure the issue – often via a reverse stock split if the price doesn’t recover organically. A Nasdaq delisting would further diminish liquidity and investor interest, so this is a situation to monitor closely. Management will likely aim to bolster the share price (through positive news or corporate actions) or enact a reverse split to maintain compliance. The low stock price also reflects financing risk: raising new equity capital at these levels would be highly dilutive, which may force the company to delay or scale back programs to avoid near-term fundraising.

Importantly, Mereo’s ability to execute its next steps is constrained by its limited cash and high R&D needs. As noted, ~$41 million in cash is a relatively slim cushion for funding a pivotal Phase 3 trial plus overhead (www.panabee.com). If the company cannot secure a development partner or alternative funding for alvelestat, it may have to postpone that trial or find other ways to reduce expenditures. There is a risk of further dilution if Mereo sells shares to raise cash – especially in the aftermath of a price crash. The company has used at-the-market (ATM) stock offerings in the past, and with the stock at fractions of a dollar, issuing a substantial number of new shares could pressure the price even more. In the worst case, if no partner or funding emerges, Mereo might be forced to significantly downsize or even explore strategic alternatives (like selling assets or the entire company) to preserve shareholder value.

Beyond financial and legal issues, execution risk remains for the pipeline that Mereo is now leaning on. The next lead candidate, alvelestat for alpha-1 antitrypsin deficiency lung disease, has shown promise in Phase 2 but still must prove itself in a Phase 3 trial. Even with regulatory alignment on trial design (www.panabee.com), there’s no guarantee the Phase 3 will succeed or that a partner will step up to co-fund it. Similarly, Mereo’s other assets are mostly out-licensed (e.g. navicixizumab for cancer, and a new program vantictumab for osteopetrosis partnered with Asahi/Astellas (Ashibio) (www.panabee.com)). While these partnerships could yield milestone payments or royalties, they are largely out of Mereo’s control and on a multi-year timeline. Any setbacks by partners could negate those potential upside milestones. The loss of Ultragenyx’s momentum on setrusumab is a red flag as well – Ultragenyx had been a strong partner, and without a clear path forward on OI, that collaboration may stall (and the up to $245 million in milestone payments under the Ultragenyx deal may never materialize) (www.panabee.com). In summary, Mereo is now a much riskier, one-program-focused company, and it must navigate legal, financial, and clinical challenges to rebuild confidence.

Open Questions and Outlook

With the class-action deadline approaching and Mereo at a crossroads, several open questions loom large:

– Can any value be salvaged from setrusumab? Mereo and Ultragenyx must decide whether to pursue some regulatory path despite the Phase 3 failure. One possibility is to argue that the robust gains in bone density could justify approval as a surrogate endpoint in OI (given the severe unmet need) (www.panabee.com) (www.panabee.com). Management has noted that in the younger COSMIC trial patients, improved BMD correlated with lower fracture rates (though not statistically significant) (www.panabee.com). The open question is whether regulators (FDA/EMA) might accept this and allow a narrow approval or an additional trial focusing on young patients. Until formal regulatory feedback is obtained, Mereo is in a holding pattern – even halting manufacturing prep for UX143 to conserve cash (www.panabee.com) (www.panabee.com). A best-case scenario might be a limited approval or a requirement for another study; worst-case, the program is abandoned. Investors are awaiting clarity on whether setrusumab has any future or is effectively a dead asset.

– What is the plan for alvelestat? This oral therapy for Alpha-1 Antitrypsin Deficiency lung disease is now Mereo’s top internal program. The company has aligned with FDA and EMA on Phase 3 trial endpoints and design (an ~220-patient, 18-month study) (www.panabee.com). Critically, Mereo has been seeking a partner to help fund and execute this trial (www.panabee.com). The question is: Can Mereo secure a partnership or co-development deal in 2026? A partnership could provide non-dilutive capital (upfront payment) and validate the asset’s potential. Without one, does Mereo have the confidence and cash to initiate Phase 3 on its own? Given the current cash levels, it seems unlikely they’d start an expensive trial solo. Thus, the timing of any alvelestat Phase 3 is uncertain. Success or failure in landing a partner will heavily influence Mereo’s outlook. If months pass without a deal, investors may worry that the program’s value isn’t convincing to potential pharma partners.

– How will the class action be resolved? Shareholders are left wondering about the impact of the lawsuit beyond the April 6, 2026 lead plaintiff deadline. Will Mereo fight the allegations in court, or consider an early settlement to limit distraction? Often, such securities class actions end in settlements funded by D&O insurance, but the discovery process could still surface unflattering information. One open question is whether any management or board changes might occur in response – e.g. if liability is pinned on specific executives or if activist investors push for further governance changes. At a minimum, the lawsuit’s progress will be an overhang. The unknowns include potential monetary damages (if it proceeds) and any non-monetary remedies (corporate governance reforms, etc.) that might be imposed.

– Will Mereo remain independent? Given its diminished market cap and mixed prospects, strategic alternative rumors could emerge. An acquirer interested in alvelestat (or even the tax assets/cash) might view Mereo as an opportunistic takeover target at these low prices. Mereo’s board – which now includes members aligned with activist shareholders – may be open to a sale or merger if it maximizes shareholder value. However, any buyer would have to weigh the lawsuit liability and the failure of setrusumab. It’s also possible Mereo could divest certain assets (for example, sell European rights of a program, or monetize its priority review voucher if one were obtained). These possibilities are speculative, but in the absence of near-term positive catalysts, investors are contemplating whether the end-game for Mereo might be a buyout or a break-up.

– How will Nasdaq compliance be addressed? If the share price doesn’t recover above $1, Mereo will likely have to execute a reverse stock split in 2026 to cure the deficiency. Management’s approach to this (timing, ratio, communication) is an open question. They may hope that announcing a partner deal or other good news lifts the stock naturally. But if not, a reverse split could be implemented to avoid delisting. Shareholders often view reverse splits with caution, as they don’t create value and sometimes precede further price declines. How Mereo navigates this issue will affect investor sentiment and the stock’s liquidity on the U.S. market.

In summary, Mereo BioPharma is at a critical inflection point. The coming months will bring answers to some of these questions. Positive developments – such as a regulatory lifeline for setrusumab or a partnership for alvelestat – could stabilize the company and restore some lost value. On the other hand, if no clear path emerges for setrusumab and funding remains elusive, Mereo may continue to stagnate or dwindle, with its stock possibly relegated to penny-stock status. Investors should keep a close eye on management’s updates and decisions in early-to-mid 2026, as they will signal how (and if) Mereo can reinvent itself after this major setback. The class action deadline of April 6, 2026 serves as a reminder of the clock ticking – both on the legal front and for the company’s need to rebuild trust and momentum (www.prnewswire.com). For now, caution is warranted, but the situation is dynamic: a single breakthrough (or misstep) could significantly alter MREO’s trajectory from here.

Sources: First-party company filings and press releases; SEC filings; and reputable financial news coverage (www.mereobiopharma.com) (www.prnewswire.com) (www.prnewswire.com) (www.sec.gov) (www.sec.gov) (www.globenewswire.com) (www.panabee.com) (www.globenewswire.com) (www.panabee.com) (www.sec.gov).

For informational purposes only; not investment advice.